Evidence map›Paper›PMID 26226895›Full record

ReviewInflammopharmacology2015

The medicinal properties and phytochemistry of plants of the genus Terminalia (Combretaceae).

I E Cock

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
31.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 212 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Flavonoids identified in AustralianMicrobiology spectrum · 2026
    Article
  7. Tropical Almond Tree (Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  8. Article
  9. Phytochemical Evaluation ofInternational journal of molecular sciences · 2025
    Article
  10. Antibacterial and Synergistic Effects ofAntibiotics (Basel, Switzerland) · 2025
    Article
  11. Flavonoids Identified inMolecules (Basel, Switzerland) · 2025
    Article
  12. Article
  13. Article
  14. Combinations ofAntibiotics (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Article
  17. Bioassay-Guided Fractionation ofPlants (Basel, Switzerland) · 2024
    Article
  18. Targeting FAK, VEGF, and MTA1 proteins withFrontiers in oncology · 2024
    Article
  19. Antibiotics (Basel, Switzerland) · 2023
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

I E CockBiomolecular and Physical Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, QLD, 4111, Australia. I.Cock@griffith.edu.au.
Griffith University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Plants of the genus Terminalia are amongst the most widely used plants for traditional medicinal purposes worldwide. Many species are used for their antibacterial, antifungal, antiprotozoal, antiviral, antidiarrhoeal, analgesic, antimalarial, antioxidant, antiinflammatory and anticancer activities. Wound healing and cardiovascular effects have also been credited to some species. Many Terminalia species have multiple beneficial effects for multiple diseases and ailments. Indeed, the Indian species Terminalia chebula is known as the king of plants in Ayurveda due to its broad range of medicinal uses. However, apart from the reported ethnopharmacological uses of many Terminalia species, surprisingly few studies have rigorously examined this important genus for their medical properties/mechanisms and phytochemistry. This is likely due to the high tannin content common to many Terminalia species and the perception that these tannins may be responsible for much of their beneficial properties. As the complexities of tannins make them poor candidates for drug design, most interest in Terminalia species has been for their pharmacognostic and nutraceutical value and they have often been overlooked as potentials for drug discovery. However, recent reports have identified many other interesting phytochemicals and demonstrated that these may be responsible for several of the reported bioactivities of the Terminalia species used in traditional medicinal systems. The last decade has seen a large increase in the number of studies into the use of Terminalia species as therapeutic agents. Several species used in Ayurvedic medicine (Terminalia arjuna, Terminalia bellerica, Terminalia catappa, T. chebula) in particular have received much recent attention. Similarly, recent reports have also highlighted the medicinal potential of species from Africa, Australia and the Americas. The aim of this report is to summarise the recent research into the medicinal properties, phytochemistry and therapeutic mechanisms of Terminalia species and thus to highlight and direct future areas of research into the medicinal activities of this important genus.

Indexed as

TerminaliaAnimalsCardiovascular DiseasesCombretaceaeCommunicable DiseasesEthnopharmacologyHumansNeoplasmsPhytotherapyPlant ExtractsPlant ExtractsAnticancerAntimicrobialAntioxidantDiabetesInflammationMedicinal plants

Identifiers

PMID26226895
OpenAlexW1092166013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.